Background/Aims: Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Methods: Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. Results: HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. Conclusions: The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment. (Korean J Hepatol 2011;17:199-205)
INTRODUCTION

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
are the major causes of chronic liver disease worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC). 1, 2 areas including Korea, the frequency of HBV infection provides the basis for an appreciable rate of HBV and HCV coinfection in the general population. 3 Some cross-sectional studies reported that in comparison with monoinfection, HBV and HCV coinfection was associated with higher prevalence of liver cirrhosis and hepatic decompensation. [5] [6] [7] Several studies also revealed that HBV and HCV coinfection increased the risk of developing HCC. [8] [9] [10] With respect to the treatment response, there was a report suggesting that HBV coinfected CHC patients responded poorly to the treatment. 11 There has been no research on coinfection of HBV and HCV in Korea, except for a report of 0.1% of anti-HCV seropositivity in HBsAg positive subjects in 2005. 12 Therefore, no sufficient recommendation for the patients with HBV and HCV coinfection was provided by the current guideline. 13 This retrospective, multicenter study aimed to investigate the prevalence of HBV and HCV coinfection in Korea, clinical and virologic characteristics, treatment efficacy of peginterferon and ribavirin combination therapy, and the change in the status of HBV infection following the treatment of CHC patients.
PATIENTS AND METHODS
Patients
HBsAg positive subjects were selected from the K(G)yeonggiIncheon Peginterferon alfa and ribavirin Effect in Chronic hepatitis C Treatment (KIPECT) study which evaluated the treatment efficacy and safety of peginterferon plus ribavirin therapy in 758 CHC patients. 14 A total of 18 HBsAg positive patients among the 758 subjects were retrospectively included from eight university hospitals. In KIPECT study, CHC patients with detectable serum HCV RNA and/or elevated serum alanine aminotransferase levels for more than 6 months, age ≥18 years, and treated with peginterferon alfa plus ribavirin from January 2000 to September 2008 were included. Exclusion criteria were acute hepatitis C patients, history of prior exposure to interferon or peginterferon, and no available data on genotype of HCV. The study protocol was approved by the Institutional Review Board of each hospital and was conducted in accordance with the principles of the Declaration of Helsinki.
Treatment of chronic hepatitis C
The study patients were treated with either pegylated interferon alfa-2a plus ribavirin or pegylated interferon alfa-2b plus ribavirin. 
Statistical analysis
The mean±standard deviation (SD) was used to describe were considered to be statistically significant. All data were analyzed using SPSS (version 15.0; Chicago, IL, USA). Figure 1 . The SVR % Figure 1 . Treatment responses according to HCV genotype. In genotype 1 (n=10), the rates of EVR (early virologic response), ETR (end of treatment response), and SVR (sustained virologic response) were 80%, 80%, and 60%, respectively; the corresponding rates in genotype 2 (n=8), were 75%, 100%, and 87.5%. , while the HBV DNA levels of the other patients remained stable. Two of the three patients with baseline HBV DNA levels >2,000 IU/mL had no detectable HBV DNA at the end of treatment.
RESULTS
Demographics and baseline characteristics
rate was 60% in genotype 1 and 87.5% in genotype 2 (Fig. 1) .
Changes in hepatitis B virus after treatment of chronic hepatitis C
Peginterferon alfa is also approved for the treatment of CHB. 13 In this study, no one developed seroclearance or seroconversion of HBsAg or HBeAg after the completion of treatment. Posttreatment HBV DNA values were available in 16 patients. The change of serum HBV DNA levels before and after treatment of CHC is presented in Figure 2 . Three patients had a baseline HBV DNA value exceeding 2,000 IU/mL and HBV DNA was undetectable in 2 of these 3 patients after the treatment. Two of the 3 patients with a baseline HBV DNA level under 2,000 IU/mL exhibited increase of HBV DNA level more than 1 log from the baseline. A 44-year-old male patient with genotype 1b infection had undetectable baseline HBV DNA (limit of detection 12 IU/mL) and was negative for HBeAg before treatment of CHC. Serum HCV RNA level was 9,340,000 IU/mL at baseline. He achieved ETR and subsequently showed SVR after the treatment with peginterferon plus ribavirin for 48 weeks, however, serum HBV DNA was increased to 4,444 IU/mL. Biochemical breakthrough or reversion of HBeAg was not observed and no additional therapy for HBV infection was administered. The clinical course of another patient who developed flare-up of CHB is presented in detail (Fig. 3A) . A 38-year-old man infected with HCV genotype 1b additionally received entecavir for HBV infection after treatment of CHC.
Baseline HBeAg was positive and serum HBV DNA was 1,552 and 0.5 mg/day of entecavir was prescribed to manage flare-up of CHB. HCV RNA was positive at 24 weeks after the treatment and SVR was not observed in this patient (Fig. 3B) .
DISCUSSION
HBV and HCV share many risk factors for infection, thus coinfection with both viruses is not uncommon. 3 However, the worldwide prevalence of coinfection with HBV and HCV is unknown due to lack of large-scale population-based studies. 4 Furthermore, since is scant information on the treatment of HBV and HCV coinfection, the current guidelines cannot suggest specific approved treatment for this patient group. 1, 13 Data from outside of Korea reported that 2-10% of CHC patients are also HBsAg positive. 4 In areas where HBV infection is endemic, like in Korea, a substantial number of patients are infected with both viruses. [17] [18] [19] Even though Korea is a HCV exerts a suppressive effect on HBV. 4, 18 This has been corroborated by reports that described the occurrence of HBeAg seroconversion and HBsAg seroclearance in HCV superinfected CHB patients. 20, 21 In our study, 88% of the study subjects were negative for HBeAg, and 83% had HBV DNA <2,000 IU/mL, which provides additional evidence for the suppression of HBV replication by HCV. Although no statistical significances were observed, HCV RNA was measured to be higher in HBeAg positive patients than that of negative patients. HCV RNA was also higher and in patients without detectable serum HBV DNA.
These finding can be another evidence of suppressive effect of HCV on HBV. While the inhibitory effect of HCV was observed only in genotype 1 HCV infection in one study, 4 it was impossible to prove this association in our study because of the small number of patients.
Combination of peginterferon alfa and ribavirin is now recommended as the standard treatment for chronic HCV monoinfection. 2 Since very limited data regarding therapy of HBV and HCV coinfected patients are available, there are currently no established treatment guidelines for these patients. 4 Although one small study reported that neither peginterferon nor conventional interferon based regimens were effective for HBV coinfected CHC, 11 a recent large randomized prospective trial from Taiwan showed that the combination therapy with peginterferon plus ribavirin was equally effective in patients with HCV monoinfection and in those with HBV and HCV coinfection. 22 Another study from China concluded that, when compared with HCV monoinfected patients, the SVR rate was similar, but relapse rate of patients with HCV genotype 1 infection in the coinfection group was high. 23 In our study, the Previous studies have indicated that successful clearance of HCV may lead to reactivation of HBV in approximately onethird of patients. [22] [23] [24] In this study, HBV DNA levels were increased after treatment of CHC in two of 13 patients (15%) whose baseline HBV DNA was <2,000 IU/mL. Although increase of HBV DNA did not result in flare-up hepatitis in one patient, biochemical breakthrough occurred in another patient and antiviral therapy against HBV was subsequently administered to manage CHB. So, while treating HBV coinfected CHC patients, the possibility of HBV reactivation should be considered even in the inactive carrier of HBV, and HBV DNA level should be carefully followed up.
Several studies have compared the histologic findings between HBV and HCV coinfection with HCV monoinfection, and concluded that liver injury or fibrosis are more severe in coinfection. 6, 22, 28 In this study, data on histology was available in only 5 patients and none of them had advanced fibrosis.
Unfortunately, due to the small number of sample size, the severity of fibrosis in HBV and HCV coinfected patients could not be evaluated in this study. There have also been several case-control studies showing an increased risk of developing HCC in coinfected patients. Therefore, evaluation about development of HCC or advanced cirrhosis in HBV and HCV coinfected patients is considered to be impossible in this study subjects and it is an area of further research.
This study has some limitations. First, the prevalence rate of HBV and HCV coinfection of 2.37% was much lower than reported data of 2-10%, 4 and there is a possibility of underestimation. We only included candidates of HCV treatment, patients with detectable HCV RNA in blood. Moreover, the proportion of CHC patients who do not require treatment due to various reasons are not considered in this study. Secondly, possible occult HBV infection was not considered. Occult HBV infection has frequently been identified in patients with HCV infection, and the prevalence has been recorded as high as 48.9%. 30, 31 The retrospective design involving a relatively small number of subjects is acknowledged drawback. Because the present study had a short follow-up period, the long-term consequence of coinfection including the development of cirrhosis or HCC could not be evaluated. Further prospective research for long-term prognosis of HBV and HCV coinfection is required.
Nevertheless, it is meaningful in that this is the first study to survey HBV and HCV coinfection in Korea, and paves the way for more comprehensive studies. Further large, multicenter, prospective studies are necessary to investigate accurate epidemiology, viral characteristics, and long term prognosis of HBV and HCV coinfection regarding the development of viral relapse, cirrhosis, and HCC. It also will be helpful to Korean guideline by collecting data from Korean population. Also, more studies are necessary to determine the optimal treatment regimen, especially to prevent HBV reactivation or elucidate the possible additional role of potent oral nucleotide/nucleoside analogues in HBV and HCV coinfected patients.
In summary, the prevalence of HBV coinfection in CHC patients was 2.37%, most of the coinfected patients had low levels of HBV DNA, and were inactive carriers. Treatment efficacy of peginterferon alfa and ribavirin combination for the coinfected patients was quite similar to patients with HCV monoinfection. After treatment of CHC and viral suppression of HCV, some patients were prone to reactivation of HBV replication.
